Zobrazeno 1 - 10
of 328
pro vyhledávání: '"Asher A. Chanan Khan"'
Autor:
Ricardo D. Parrondo, Betsy R. LaPlant, Jamie Elliott, Andre Fernandez, Caitlin J. Flott, Diedre Arrington, Dustin Chapin, Jade Brown, Saurav Das, Vivek Roy, Asher A. Chanan-Khan, Sikander Ailawadhi
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/91c6bdbb2c0244cbb8d319fe7979abc9
Autor:
Sikander Ailawadhi, Yaw Adu, Ryan D. Frank, Saurav Das, David O. Hodge, Andre Fernandez, Caitlyn Flott, Jamie Elliott, Ricardo Parrondo, Taimur Sher, Vivek Roy, Asher A. Chanan-Khan
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Abstract Multiple myeloma (MM) therapeutics have evolved tremendously in recent years, with significant improvement in patient outcomes. As newer treatment options are developed, stem cell transplant (SCT) remains an important modality that provides
Externí odkaz:
https://doaj.org/article/89dae84d967e4beb847fa9314239a4a1
Autor:
Sikander Ailawadhi, Meghna Ailawadhi, Navnita Dutta, Ricardo D. Parrondo, Vivek Roy, Taimur Sher, Mizba Baksh, Ahsan Rasheed, Saurav Das, Andre J. Fernandez, Aneel Paulus, Asher A. Chanan‐Khan
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 19013-19020 (2023)
Abstract Introduction Health information technology (HIT) has the potential to improve healthcare delivery and engagement. Studying racial‐ethnic disparities in HIT engagement will help understand and overcome challenges to healthcare utilization.
Externí odkaz:
https://doaj.org/article/1a893cfa3efb441eb05f8da1cd56f354
Autor:
Paul J. Hampel, Kari G. Rabe, Timothy G. Call, Wei Ding, Jose F. Leis, Asher A. Chanan-Khan, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Sikander Ailawadhi, Amber B. Koehler, Ricardo Parrondo, Susan M. Schwager, Taimur Sher, Curtis A. Hanson, Min Shi, Daniel L. Van Dyke, Esteban Braggio, Susan L. Slager, Neil E. Kay, Sameer A. Parikh
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 9, Pp 1-6 (2022)
Abstract Patients with chronic lymphocytic leukemia (CLL) with disease progression on ibrutinib have worse outcomes compared to patients stopping ibrutinib due to toxicity. A better understanding of expected outcomes in these patients is necessary to
Externí odkaz:
https://doaj.org/article/c5ee38417b3b4e7f8218d469cd1ba54f
Autor:
Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay Nooka, Hang Quach, Markus Munder, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, Tineke Casneuf, Nikki DeAngelis, Himal Amin, Jon Ukropec, Rachel Kobos, Maria-Victoria Mateos
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-11 (2020)
Abstract Background Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exh
Externí odkaz:
https://doaj.org/article/f4bcd4b8584c4c2d8d002b323f628268
Autor:
Sameer A. Parikh, Sara J. Achenbach, Timothy G. Call, Kari G. Rabe, Wei Ding, Jose F. Leis, Saad S. Kenderian, Asher A. Chanan‐Khan, Amber B. Koehler, Susan M. Schwager, Eli Muchtar, Amie L. Fonder, Kristen B. McCullough, Adrienne N. Nedved, Matthew D. Smith, Susan L. Slager, Neil E. Kay, Heidi D. Finnes, Tait D. Shanafelt
Publikováno v:
Cancer Medicine, Vol 9, Iss 10, Pp 3390-3399 (2020)
Abstract To study the impact of dose modification and temporary interruption of ibrutinib in routine clinical practice, we conducted a retrospective study of consecutive CLL patients treated with ibrutinib outside the context of a clinical trial at M
Externí odkaz:
https://doaj.org/article/ec5898c07904452d8346728e1b2de5a5
Autor:
Claudia C. S. Chini, Thais R. Peclat, Lilian S. Gomez, Julianna D. Zeidler, Gina M. Warner, Sonu Kashyap, Delaram Z. Mazdeh, Faisal Hayat, Marie E. Migaud, Aneel Paulus, Asher A. Chanan-Khan, Eduardo N. Chini
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Nicotinamide adenine dinucleotide (NAD) metabolism plays an important role in the regulation of immune function. However, a complete picture of how NAD, its metabolites, precursors, and metabolizing enzymes work together in regulating immune function
Externí odkaz:
https://doaj.org/article/502ecd85233d4cc494866e8e51f97875
Autor:
Yucai Wang, Kari G. Rabe, Michael S. Bold, Min Shi, Curtis A. Hanson, Susan M. Schwager, Timothy G. Call, Saad S. Kenderian, Eli Muchtar, Suzanne R. Hayman, Amber B. Koehler, Amie L. Fonder, Asher A. Chanan-Khan, Daniel L. Van Dyke, Susan L. Slager, Neil E. Kay, Wei Ding, Jose F. Leis, Sameer A. Parikh
Publikováno v:
Haematologica, Vol 105, Iss 11 (2020)
Externí odkaz:
https://doaj.org/article/583604c4d80b473c848de91a69758bf4
Autor:
Ricardo D. Parrondo, Vivek Roy, Taimur Sher, Victoria Alegria, Asher A. Chanan-Khan, Sikander Ailawadhi
Publikováno v:
Case Reports in Hematology, Vol 2020 (2020)
Extramedullary multiple myeloma is defined by the presence of plasma cell infiltration outside of the bone marrow. It is associated with a poor prognosis and resistance to therapy and is often associated with high-risk cytogenetics. Aggressive relaps
Externí odkaz:
https://doaj.org/article/aca4fb72818c4b72812a69bf3629905e
Autor:
Muhamad Alhaj Moustafa, Ricardo Parrondo, Mays F. Abdulazeez, Vivek Roy, Taimur Sher, Victoria R. Alegria, Rahma M. Warsame, Rafael Fonseca, Ahsan Rasheed, Wilson I. Gonsalves, Taxiarchis Kourelis, Prashant Kapoor, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Craig B. Reeder, Asher A. Chanan-Khan, Sikander Ailawadhi
Publikováno v:
Anti-Cancer Drugs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5564f91cbb0edd3e99e8c61023748da7
https://doi.org/10.1097/cad.0000000000001520
https://doi.org/10.1097/cad.0000000000001520